Meeting
2014 Gastrointestinal Cancers Symposium
The biomarkers of gemcitabine and erlotinib treatment in advanced pancreatic cancer.
Authors
Kuniyasu Irie
Division of Hepatobiliary and Pancreatic Oncology, Kanagawa Cancer Center, Yokohama, Japan
Kuniyasu Irie , Makoto Ueno , Satoshi Kobayashi , Yoshihiro Gouda , Shinichi Ohkawa , Morimoto Manabu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 358)
DOI
10.1200/jco.2014.32.3_suppl.358
Abstract #
358
Poster Bd #
D17
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center.
First Author: Jennifer Brooke Goldstein
Poster
2013 Gastrointestinal Cancers Symposium
Phosphorylated ERK (pERK) as biomarker in patients with advanced pancreatic cancer treated with erlotinib within a randomized phase III trial (AIO-PK0104).
First Author: Stefan Boeck
Poster
2018 Gastrointestinal Cancers Symposium
RX3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer—Preliminary results of stage II of the phase Ia/IIb study.
First Author: Vincent M. Chung
Poster
2017 Gastrointestinal Cancers Symposium
A phase II study of gemcitabine, erlotinib, and S-1 in patients with advanced pancreatic cancer.
First Author: Boram Han